Patents by Inventor Klaus Langer

Klaus Langer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220047705
    Abstract: The present invention generally relates to the formation, chemistry and application of biologically active compositions. More particularly, the present invention relates to certain dyes, specifically porphyrin and chlorin derivatives, in combination with inventive polymers, i.e. light-cleavable polymers, that can be used as photosensitizer compositions for a wide range of light irradiation treatments such as photodynamic therapy of cancer, infections and other diseases. The dye derivatives may either be adsorbed on, or incorporated in, or attached to specific polymers, which as well form part of the invention.
    Type: Application
    Filed: September 24, 2019
    Publication date: February 17, 2022
    Applicants: WESTFÄLISCHE WILHELMS-UNIVERSITÄT MÜNSTER, UNIVERSITÄT PADERBORN, BIOLITEC RESEARCH GMBH
    Inventors: Klaus LANGER, Juliane ANDERSKI, Laura MAHLERT, Dennis MULAC, Dirk KUCKLING, Jingjiang SUN, Wolfgang BIRNBAUM, Arno WIEHE, Gerhard Dieter WIELAND, Volker ALBRECHT
  • Patent number: 9211283
    Abstract: Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for photodynamic therapy comprising a hydrophobic photosensitizer, human serum albumin (HSA) and stabilizing agent are provided. These nanoparticulate formulations provide therapeutically effective amounts of photosensitizer (PS) for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers whose efficacy and safety are enhanced by such nanoparticulate formulations. A method of preparing the HSA-based nanoparticles under sterile conditions is also provided. In one of the preferred embodiments of the present invention temoporfin, a hydrophobic PS, is formulated as a nanoparticle for parenteral administration. The formulations are useful for treating hyperplasic and neoplasic conditions, inflammatory problems, and more specifically to target tumor cells.
    Type: Grant
    Filed: November 8, 2010
    Date of Patent: December 15, 2015
    Assignee: Biolitec Pharma Marketing Ltd
    Inventors: Klaus Langer, Matthias Wacker, Beate Röder, Annegret Preuss, Volker Albrecht, Susanna Gräfe, Arno Wiehe, Hagen von Briesen, Karin Löw, Sylvia Wagner
  • Patent number: 8840879
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a covalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: September 23, 2014
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
  • Patent number: 8420215
    Abstract: A cyclic process for the preparation of barium sulphate and lithium-iron phosphate comprising (i) preparing an aqueous solution containing lithium and sulphate ions and (ii) adding solid barium hydroxide at a temperature of more than 50° C., wherein the barium hydroxide is added over a period of less than 15 minutes. Also, barium sulphate obtainable by the process according to the invention.
    Type: Grant
    Filed: July 14, 2008
    Date of Patent: April 16, 2013
    Assignee: Sued-Chemie IP GmbH & Co. KG
    Inventors: Christian Vogler, Klaus Langer, Andreas Pollner, Gerhard Nuspl
  • Publication number: 20120263739
    Abstract: The invention relates to anti-integrin antibodies which are covalently linked to nanoparticles, wherein these nanoparticles were prior loaded with chemotherapeutic/cytotoxic agents. The antibody-chemotherapeutic agent-nanoparticle conjugates according to the invention, especially wherein the antibody is MAb DI17E6 and the cytotoxic agent is doxorubicin show a significant increase of tumor cell toxicity.
    Type: Application
    Filed: October 21, 2010
    Publication date: October 18, 2012
    Applicant: MERCK PATENT GMBH
    Inventors: Klaus Langer, Marion Anhorn, Joerg Kreuter, Florian Rothweiler, Hagen von Briesen, Sylvia Wagner, Martin Michaelis, Jindrich Cinatl
  • Patent number: 8287850
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided. The conjugates are formed by a reductive amination reaction between at least one aldehyde group or keto group or hemiacetal group of the hydroxyalkyl starch or of a derivative of the hydroxyalkyl starch, and at least one amino group of the protein, so that the hydroxyalkyl starch or the derivative thereof is covalently linked to the protein via an azomethine linkage or a amino linkage. Methods of producing these conjugates and specific uses of the conjugates also are provided.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: October 16, 2012
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Wolfram Eichner, Michele Orlando, Norbert Zander, Harald S. Conradt, Frank Hacket, Klaus Langer, Ronald Frank
  • Publication number: 20110275686
    Abstract: Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for clinical use in photodynamic therapy comprising a hydrophobic photosensitizer, poly(lactic-co-glycolic) acid and stabilizing agents are provided. These nanoparticulate pharmaceutical formulations provide therapeutically effective amounts of photosensitizer for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers, whose efficacy and safety are enhanced by such nanoparticulate formulations. It also teaches the method of preparing PLGA-based nanoparticles under sterile conditions. In one of the preferred embodiments of the present invention PLGA-based nanoparticles have a mean particle size less than 500 nm and the photosensitizer is temoporfin, 5,10,15,20-tetrakis(3-hydroxyphenyl)-chlorin (mTHPC).
    Type: Application
    Filed: November 8, 2010
    Publication date: November 10, 2011
    Inventors: Klaus Langer, Thomas Knobloch, Beate Röder, Annegret Preuß, Volker Albrecht, Susanna Gräfe, Arno Wiehe, Hagen von Briesen, Karin Löw, Sylvia Wagner
  • Patent number: 8017739
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
    Type: Grant
    Filed: September 8, 2006
    Date of Patent: September 13, 2011
    Assignee: Fresenius Kabi Deutschland GmbH
    Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
  • Publication number: 20110200555
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
    Type: Application
    Filed: February 1, 2011
    Publication date: August 18, 2011
    Applicant: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
  • Publication number: 20110142948
    Abstract: Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for photodynamic therapy comprising a hydrophobic photosensitizer, human serum albumin (HSA) and stabilizing agent are provided. These nanoparticulate formulations provide therapeutically effective amounts of photosensitizer (PS) for parenteral administration. In particular, tetrapyrrole derivatives can be used as photosensitizers whose efficacy and safety are enhanced by such nanoparticulate formulations. A method of preparing the HSA-based nanoparticles under sterile conditions is also provided. In one of the preferred embodiments of the present invention temoporfin, a hydrophobic PS, is formulated as a nanoparticle for parenteral administration. The formulations are useful for treating hyperplasic and neoplasic conditions, inflammatory problems, and more specifically to target tumor cells.
    Type: Application
    Filed: November 8, 2010
    Publication date: June 16, 2011
    Inventors: Klaus Langer, Matthias Wacker, Beate Röder, Annegret Preuss, Volker Albrecht, Susanna Gräfe, Arno Wiehe, Hagen von Briesen, Karin Löw, Sylvia Wagner
  • Publication number: 20100255308
    Abstract: A cyclic process for the preparation of barium sulphate and lithium-iron phosphate comprising (i) preparing an aqueous solution containing lithium and sulphate ions and (ii) adding solid barium hydroxide at a temperature of more than 50° C., wherein the barium hydroxide is added over a period of less than 15 minutes. Also, barium sulphate obtainable by the process according to the invention.
    Type: Application
    Filed: July 14, 2008
    Publication date: October 7, 2010
    Inventors: Christian Vogler, Klaus Langer, Andreas Pollner, Gerhard Nuspl
  • Publication number: 20100028446
    Abstract: Combination preparations comprising at least one apolipoprotein as one component, and a medicinal agent to be transported via the blood-brain barrier to the central nervous system as a further component. The components are administered simultaneously, separately or sequentially. A method for administering a medicinal agent to the central nervous system is also provided.
    Type: Application
    Filed: February 1, 2008
    Publication date: February 4, 2010
    Inventors: Jörg Kreuter, Klaus Langer, Sebastian Dreis, Telli Hekmatara
  • Publication number: 20090304720
    Abstract: Active agent-loaded nanoparticles that are based on a hydrophilic protein or a combination of hydrophilic proteins, and methods for producing the nanoparticles and the use thereof. Functional proteins or peptide fragments are bound to the nanoparticles via polyethylene glycol-?-maleimide-?-NHS esters.
    Type: Application
    Filed: February 27, 2007
    Publication date: December 10, 2009
    Applicant: LTS Lohmann Therapie-Systeme AG
    Inventors: Jörg Kreuter, Klaus Langer, Kerstin Michaelis, Telli Hekmatara, Sebastian Dreis
  • Publication number: 20090181090
    Abstract: Nanoparticles, the particle matrix of which is based on at least one protein and has at least one active agent embedded therein and methods of producing the nanoparticles with at least one active agent embedded in the protein matrix are disclosed. The use of the nanoparticles for the treatment of tumours, in particular for the treatment of tumours which are resistant to chemical medicaments is also disclosed.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 16, 2009
    Inventors: Sebastian Dreis, Klaus Langer, Jörg Kreuter, Martin Michaelis, Jindrich Cinatl
  • Publication number: 20090047251
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided herein. The conjugates are formed by a convalent linkage between the hydroxyalkyl starch or a derivative of the hydroxyalkyl starch and the protein. Methods of producing the conjugates and the use of the conjugates also are provided herein.
    Type: Application
    Filed: September 8, 2006
    Publication date: February 19, 2009
    Inventors: Wolfram Eichner, Martin Schimmel, Frank Hacket, Elmar Kraus, Norbert Zander, Ronald Frank, Harald Conradt, Klaus Langer, Michele Orlando, Klaus Sommermeyer
  • Publication number: 20080095857
    Abstract: A carrier system in the form of protein-based nanoparticles for the cell-specific, intracellular enrichment of at least one pharmacologically active substance. The system has structures that are coupled by reactive groups. The structures enable a cell-specific attachment and cellular absorption of the nanoparticles.
    Type: Application
    Filed: March 2, 2005
    Publication date: April 24, 2008
    Applicant: LTS LOHMANN THERAPIE-SYSTEME AG LOHMANNSTRASSE 2
    Inventors: Sabine Balthasar, Hagen Von Briesen, Norbert Dinauer, Jorg Kreuter, Klaus Langer, Heidrun Wartlick
  • Publication number: 20070134197
    Abstract: Conjugates of hydroxyalkyl starch and a protein are provided. The conjugates are formed by a reductive amination reaction between at least one aldehyde group or keto group or hemiacetal group of the hydroxyalkyl starch or of a derivative of the hydroxyalkyl starch, and at least one amino group of the protein, so that the hydroxyalkyl starch or the derivative thereof is covalently linked to the protein via an azomethine linkage or a amino linkage. Methods of producing these conjugates and specific uses of the conjugates also are provided.
    Type: Application
    Filed: September 8, 2006
    Publication date: June 14, 2007
    Inventors: Wolfram Eichner, Michele Orlando, Norbert Zander, Harald Conradt, Frank Hacket, Klaus Langer, Ronald Frank
  • Publication number: 20040131692
    Abstract: The present invention relates to nanoparticles for penetrating the blood-brain barrier. The nanoparticles are characterized in that they consist of a hydrophile protein or of a combination of hydrophile proteins, preferably of serum albumin, with particular preference of human origin, to which apolipoprotein E is coupled. The invention further relates to processes for the manufacture of such nanoparticles.
    Type: Application
    Filed: February 11, 2004
    Publication date: July 8, 2004
    Inventors: Joerg Kreuter, Klaus Langer, Carolin Weber, Renad N. Alyautdin
  • Patent number: 6526794
    Abstract: The invention relates to a plate for a spin drum in a centrifuge. The plates contain integrally formed spacers. These plate spacers are comprised of plate material thickenings and are designed to maintain an intermediate space between two or more plates stacked on top of each other. To create this design, the invention includes a process for the manufacture of the plate as defined above. This process includes the step of roll-pressing a blank over a cone shaped mandrel provided with depressions conforming to the shapes of the spacers of the plate. During this rolling process, the spacers are formed when the depressions in the mandrel are filled with the material of the blank. To ease in the formation of these spacers, the blank may be heated prior to rolling.
    Type: Grant
    Filed: June 7, 2000
    Date of Patent: March 4, 2003
    Assignee: Südmo Schleicher AG
    Inventors: Klaus Langer, Klaus Pardess, Dittmar Holm, Albrecht Gruneisen
  • Patent number: 5089492
    Abstract: Acylamino carboxylic acid derivatives corresponding to the formula I ##STR1## in which the groups R.sup.1, R.sup.2, R.sup.3, Z.sup.1 and Z.sup.2 represent functional groups specified in the claims. The acylamino carboxylic acid derivatives have valuable pharmacological properties which, in particular, favorably influence nitrogen metabolism. The compounds are useful as active ingredients in pharmaceutical and/or dietetic compositions for treatment or prevention of nitrogen metabolism disturbances in large mammals caused, for example, by liver or kidney damage.
    Type: Grant
    Filed: May 24, 1990
    Date of Patent: February 18, 1992
    Assignees: Kali-Chemie AG, Pfrimmer Kabi GmbH & Co. KG
    Inventors: Klaus Gerling, Henning Heinemanmn, Andreas Meier, Klaus Langer